SCHEMBL1126669

SCHEMBL1126669

Cc1ccccc1CSSc1ccccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 1/20 0.52
EHMT1 Q9H9B1 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52
SLC1A2 P43004 1/20 0.50
NPC1 O15118 3/20 0.45
RAB9A P51151 2/20 0.45
L3MBTL1 Q9Y468 4/20 0.44
POLB P06746 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 3/20 0.39
GAA P10253 1/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29587981 0.83 SLC1A2 (0.64) APOBEC3GSLC1A2NPC1RAB9AL3MBTL1
SCHEMBL28790425 0.80 EHMT2 (0.52) EHMT2EHMT1APOBEC3GL3MBTL1POLB
SCHEMBL16710901 0.80 APOBEC3G (0.52) EHMT2EHMT1APOBEC3GNPC1RAB9A
SCHEMBL16710804 0.78 EHMT2 (0.48) EHMT2EHMT1APOBEC3GNPC1RAB9A
SCHEMBL1126670 0.77 EHMT2 (0.52) EHMT2EHMT1APOBEC3GNPC1RAB9A
SCHEMBL12729631 0.76 EHMT2 (0.47) EHMT2EHMT1APOBEC3GNPC1RAB9A
SCHEMBL775626 0.75 TAAR1 (0.50) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL537743 0.75 EHMT2 (0.59) EHMT2EHMT1APOBEC3GNPC1RAB9A
SCHEMBL17833858 0.75 ALDH1A1 (0.57) EHMT2EHMT1APOBEC3GNPC1RAB9A
SCHEMBL327697 0.74 EHMT2 (0.64) EHMT2EHMT1APOBEC3GNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361302-A1 ANTI-PD-1 IMMUNOGLOBULIN POLYPEPTIDES AND USES THEREOF TUFTS COLLEGE (US) 2025-11-27 US disclosed
EP-4490168-A1 CTLA-4 BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND USES THEREOF Molecular Templates, Inc. (US) 2025-01-15 EP disclosed
US-12180262-B2 CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors MOLECULAR TEMPLATES, INC. (US) 2024-12-31 US disclosed
US-12065469-B2 De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals MOLECULAR TEMPLATES, INC. (US) 2024-08-20 US disclosed
US-20240092860-A1 CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2024-03-21 US disclosed
US-20240082404-A1 SHIGA TOXIN A SUBUNIT EFFECTOR POLYPEPTIDES, SHIGA TOXIN EFFECTOR SCAFFOLDS, AND CELL-TARGETING MOLECULES FOR SITE-SPECIFIC CONJUGATION ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2024-03-14 US disclosed
US-11918649-B2 PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds MOLECULAR TEMPLATES, INC. (US) 2024-03-05 US disclosed
US-20230331785-A1 HER2-TARGETING MOLECULES COMPRISING DE-IMMUNIZED, SHIGA TOXIN A SUBUNIT SCAFFOLDS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-10-19 US disclosed
WO-2023172983-A1 CTLA-4 BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND USES THEREOF MOLECULAR TEMPLATES, INC. (US) 2023-09-14 WO disclosed
US-11713347-B2 CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors MILLENNIUM PHARMACEUTICALS, INC. (US) 2023-08-01 US disclosed
WO-2020190733-A1 pHLIP®-MEDIATED TARGETING OF CORTICOSTEROIDS TO DISEASED TISSUE UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) 2020-09-24 WO disclosed
WO-2020154531-A1 CD38-BINDING PROTEINS COMPRISING DE-IMMUNIZED SHIGA TOXIN A SUBUNIT EFFECTORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2020-07-30 WO disclosed
WO-2017046658-A1 DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE HANGZHOU DAC BIOTECH CO, LTD (CN) 2017-03-23 WO disclosed
EP-2283042-A2 ISOLATED MONOCLONAL ANTIBODY OR FRAGMENT THEREOF BINDING PROSTATE SPECIFIC MEMBRANE ANTIGEN, CONJUGATES AND USES THEREOF Università Degli Studi Di Verona (IT) 2011-02-16 EP disclosed
EP-1713514-A2 DRUGS AND GENE CARRIER PARTICLES THAT RAPIDLY MOVE THROUGH MUCOUS BARRIERS The Johns Hopkins University (US) 2006-10-25 EP disclosed
WO-2005072710-A2 DRUGS AND GENE CARRIER PARTICLES THAT RAPIDLY MOVE THROUGH MUCOUS BARRIERS JOHNS HOPKINS UNIVERSITY (US) 2005-08-11 WO disclosed
EP-1436429-A2 TARGETED NUCLEIC ACID CONSTRUCTS AND USES RELATED THERETO THE GENERAL HOSPITAL CORPORATION (US) 2004-07-14 EP disclosed
WO-2003020949-A2 TARGETED NUCLEIC ACID CONSTRUCTS AND USES RELATED THERETO THE GENERAL HOSPITAL CORPORATION (US) 2003-03-13 WO disclosed
EP-1135411-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS INVOLVING EXCITOTOXICITY BIOGEN, INC. (US) 2001-09-26 EP disclosed
WO-2000035948-A1 METHODS AND COMPOSITIONS FOR TREATING DISORDERS INVOLVING EXCITOTOXICITY BIOGEN, INC. (US) 2000-06-22 WO disclosed